(ACEI)
end-stage renal disease (ESRD) requiring maintenance dialysis [1] [2] [3] [4] , and is associated with increased morbidity and mortality [1] [2] [3] 5 . For many of these patients, kidney transplantation is a preferred option of renal replacement therapy to correct metabolic abnormalities. It is assumed that hypervolemia no longer represents a major problem following transplantation, but no study to date confirms or refutes this.
In addition, hypervolemia is associated with hypertension in patients on haemodialysis 2 and peritoneal dialysis 3 , but this relationship has not been studied in kidney transplant recipients (KTRs) despite this complication arising in 75-90% of these patients 6 .
B-type Natriuretic Peptide (BNP) is a cardiac hormone that is synthesized as an amino acid precursor protein and undergoes intracellular modification to a Prohormone BNP (pro-BNP) 7 .
It is secreted predominately from the ventricles in response to increased stretch of the ventricular wall 7 . Upon release into the circulation, pro-BNP is cleaved into the biologically active 32-amino acid C-terminal fragment BNP, and the biologically inactive 76-amino acid Nterminal fragment (NT-proBNP) 7 . NT-proBNP possesses a longer half-life time than the biologically active counterpart, hence delivering a superior reflection of pathophysiological situation leading to raised BNP levels 8 . Due to renal metabolism of NT-proBNP, Post-print cite as: Chan, W., Jones, D., Bosch, J.A., McTernan, P.G., Inston, N., Moore, S., Kaur, O., Phillips, A.C. & Borrows, R. (2014). Hypervolemia and blood pressure in prevalent kidney transplant recipients. Transplantation, 98, 320-327. http://dx.doi.org/10.1097/TP.0000000000000066 concentrations also rise with the progression of chronic kidney disease (CKD) 9 . Recent studies have confirmed that it is a marker of extracellular volume overload rather than cardiac dysfunction per se in maintenance dialysis patients [10] [11] [12] [13] . However, little research has examined this relationship following transplantation, with the 2 studies conducted to date highlighting the inverse relationship between NT-proBNP and allograft function 14, 15 .
The primary objectives of this study were to determine the prevalence and predictors for hypervolemia in a stable kidney transplant cohort, and to assess its association with posttransplant hypertension. Secondly, we sought to explore the utility of serum NT-proBNP as a correlate of hypervolemia and renal dysfunction in this cohort.
Results

Population characteristics
The characteristics of the studied population are shown in Table 1 . The mean percentage volume expansion (%VE) ± standard deviation (SD) for the cohort was 2.6±7.7%, ranging from -17.0% to +25.0%. Based on denoted criteria (described in Materials and Methods), the prevalence of hypovolemia in KTRs was 11% (13 patients), normovolemia was 59% (73 patients), mild hypervolemia was 25% (31 patients displaying %VE between 7.1 and 15.0%), and 5% suffered from severe hypervolemia (6 patients displaying %VE >15.0%).
Post-print cite as: Chan, W., Jones, D., Bosch, J.A., McTernan, P.G., Inston, N., Moore, S., Kaur, O., Phillips, A.C. & Borrows, R. (2014). Hypervolemia and blood pressure in prevalent kidney transplant recipients. Transplantation, 98, 320-327. http://dx.doi.org/10.1097/TP.0000000000000066
Factors predicting extracellular volume status
On univariate analysis, increasing values for %VE were associated with the following: higher sodium intake (relationship is shown in Figure 1 ), higher fluid intake, older age, pre-existing diabetes, male gender, the use of either an angiotensin-converting-enzyme-inhibitor (ACEI) or angiotensin-receptor blocker (ARB) (grouped as a single category), and the number of antihypertensive medications. The effect sizes for the univariate analyses are shown in SDC, Figure   2a ). A significant difference across categories of volume status ("hypovolemia";
"normovolemia"; "mild hypervolemia"; "severe hypervolemia") was seen, with increased BP at higher degrees of extracellular volume status (Figure 2b ). Figure 3 ), older age, diabetes (either pre-existing diabetes, pre-DM; or new onset diabetes after transplantation, NODAT), the use of either an ACEI or ARB, hypoalbuminaemia, male gender, and number of antihypertensive medications. In addition, higher fluid intake was associated with higher MAP and SBP readings, but not DBP. However, in the adjusted model, the only independent predictor of BP was a higher %VE, with this effect seen for MAP (β = 6.6; 95% CI = 5.6, 7.6; p<0.001), SBP (β = 9.8; 95% CI = 8.5, 11.0;
p<0.001), and DBP (β = 4.9; 95% CI = 3.7, 6.2; p<0.001). Of note, a substantial proportion of BP variation could be explained by this single predictor variable (62%, 69% and 35% for MAP, SBP and DBP as shown in SDC, Table 2; SDC, Table 3 ; and SDC, Table 4 respectively). Figure   4a and Figure 4b respectively. A 21% of the variation in NT-proBNP was explained by the variables in the final multivariate model.
NT-proBNP as a marker of hydration status and allograft function
Discussion
This is the first study to address in detail the prevalence, predictors, and consequences of hypervolemia in KTRs. Based on the previously established definition of hypervolemia, 30%
of KTRs were hypervolemic, of whom 5% suffered from severe hypervolemia. 25, 26 . In the current study, the prevalence of diuretic usage was only 15%, with furosemide being the only diuretic prescription. No association between furosemide usage and volume status was observed, but this may be a reflection of "confounding by indication". Furthermore, the median dosage of furosemide in this study cohort was 40mg, a dosage which may be insufficient to target hypervolemia in KTRs with a mean eGFR of 44mL/min 27 . Such confounding may also be responsible for the association between renin-angiotensin system blockers (ACEI and ARB), and volume overload, MAP, SBP and DBP, although these associations did not persist in the adjusted analysis.
In regard to other determinants of extracellular volume status, an inverse association between fat mass and volume status was observed in the current study. This phenomenon has been demonstrated in a non-transplanted population 28 , which now extends to the kidney transplant The independent association between an objective measure of hypervolemia and raised NTproBNP level is a novel and noteworthy finding of this study, confirming and extending findings from the non-transplanted populations, predominantly patients undergoing dialysis [10] [11] [12] [13] . Additionally, reduced allograft function was independently associated with raised NTproBNP levels, in keeping with findings from previous studies among KTRs 14, 15 , due to a reduced renal clearance of NT-proBNP. Although previous studies have suggested NTproBNP as a marker of cardiac dysfunction in dialysis patients 37, 38 , interpretation of these studies is limited by a lack of concomitant and objective measurement of volume status, and by the variation in NT-proBNP levels depending on the timing of blood sampling relative to dialysis treatment. In fact, the most detailed study in dialysis which employed standardised sampling times, simultaneous echocardiography and bioimpedance-based extracellular fluid volume measurements, showed that NT-proBNP was dependent on volume overload per se, rather than the echocardiographic parameters of cardiac dysfunction 10,11 . The single study in KTRs addressing the relationship between echocardiography and NT-proBNP level likewise found no relationship between the two parameters 14 . Whilst cardiac function was not assessed in the current study, the findings from this study certainly support the concept that NT-proBNP levels reflect volume status. However, an important caveat is the high variability in the relationship between NT-proBNP levels and both %VE and eGFR. This suggests that although NT-proBNP may be a marker of volume expansion and renal dysfunction, it cannot yet be considered as an accurate surrogate for either. The utility of serial NT-proBNP measurements cannot be discerned by the current study.
Other factors independently associated with elevated NT-proBNP levels included smoking (current and/or ex-smoker), reduced level of Hb, and the absence of CCB prescription as an antihypertensive agent. Although the mechanisms behind these findings are not fully understood and were not the focus of the present study, these results are in keeping with previous observations in non-transplant cohorts [39] [40] [41] [42] [43] [44] [45] , and reflecting the "face validity" of the current findings.
This study has limitations that should be acknowledged. It represents a single-centre experience, and validations of the findings are needed in other cohorts. Also, transplant renal artery stenosis is a potential cause for post-transplant hypertension and volume expansion.
However, it was not systematically sought in this study due to an estimated prevalence of only 5-10% 46 , and the lack of detection is unlikely to have confounded the results. The crosssectional nature of this study is unable to establish the causal relationship between predictor and outcome variables. Long-term longitudinal follow-up and experimental interventions are now required to robustly evaluate the impact of extracellular volume status on relevant endpoints in kidney transplantation.
In summary, this is the first study to investigate the prevalence, predictors, consequences, and biochemical markers of hypervolemia in KTRs. It points at potential targets for intervention, thereby expanding future avenues for basic and clinical research.
Materials and Methods
Participants and study design
KTRs beyond 1 year post-transplantation, with stable graft function (<10% increase in serum creatinine over preceding 6 months), were recruited to this cross-sectional study between April Six readings over an 8-10 minute period were taken, with the first reading ignored, and the mean of the remaining 5 used for analysis. This protocol for BP monitoring has been shown to produce measurements comparable to that derived from the 24-hour ambulatory blood pressure monitor, the "gold standard" for the diagnosis of hypertension 47 . Mean arterial pressure (MAP) was subsequently calculated using the formula (2DBP + SBP)/3 18 .
Laboratory parameters
Blood samples were collected for measurement of high-sensitivity C-reactive protein (hsCRP), albumin (Alb), haemoglobin (Hb) and estimated glomerular filtration rate (eGFR) derived using 4-variable modification of diet in renal disease equation 48 . Morning urine was collected for assessment of albumin : creatinine ratio (ACR). Analyses were undertaken in accredited hospital haematology and biochemistry laboratories.
Post
Serum NT-proBNP was measured using a non-competitive immunoluminometric assay as described by Khan and colleagues 49 . This highly specific assay shows no cross-activity with atrial natriuretic peptide, BNP, or C-type natriuretic peptide 49 . The inter-and intra-assay coefficients of variation were 2.3 and 4.8% respectively 49 .
Sodium and fluid intakes
Sodium and fluid intakes were estimated by a 3-day food diary. A multiple-day food diary provides a good estimate of individual's sodium intake 50 , comparable to that derived from the mean 24-hour urinary sodium excretion 50,51 , and produces a reliable and valid record of fluid intake in free-living humans 52 . Participants were given detailed written instructions on completing an accurate dietary record for a 3-day period, which included one weekend day, within one week prior to attending the research visit. These instructions were accompanied by verbal explanation from the researcher, which included training in portion size estimation and documentation for both dining in and eating out. The dietary records were reviewed by the researcher for accuracy and completeness at the research visit. Data was entered into Dietplan6 P3 (Forestfield Software Ltd) nutrition analysis program by the same researcher, avoiding inter-observer variation. Total daily intakes of fluid, energy, all macro-and micro-nutrients, were calculated by this program. No patients were prescribed sodium-containing oral medication at the time of the study.
Measurement of body composition and hydration status; definition of fluid overload
Post-print cite as: Chan, W., Jones, D., Bosch, J.A., McTernan, P.G., Inston, N., Moore, S., Kaur, O., Phillips, A.C. & Borrows, R. (2014). Hypervolemia and blood pressure in prevalent kidney transplant recipients. (and those used in the current study) are based on %VE, <-7.0% representing "hypovolemia", within ±7.0% indicating "normovolemia", between 7.1% and 15.0% denoting "mild hypervolemia", and >15.0% demonstrating "severe hypervolemia".
Measurements were carried out in a standard manner while the patient was lying supine in a flat and non-conductive bed. The inbuilt physiological body composition model measures wholebody bioimpedance spectroscopy at 50 frequencies (5 to 1000 kHz) via electrodes placed on the wrist (proximal to the transverse) and the ankle (arch on the superior side of the foot) on the 
Statistical analysis
Statistical analyses were performed using STATA. Results were presented as mean ± standard deviation (SD) for normally distributed data or median (interquartile range, IQR) for nonnormally distributed data. Unadjusted univariate relationships were evaluated with Pearson's correlation coefficients, and one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test for multiple-group comparisons.
Linear regression analysis was used to determine the associations between predictor variables and the continuously-distributed outcome variables, with logarithmic transformation of nonnormally distributed data prior to analysis. The analyses were performed in two stages.
Initially, the effect of each variable was examined in a series of univariate regression analyses.
Subsequently, the joint effect of variables demonstrating some evidence of association on univariate analysis (p<0.20) was examined in a multivariable regression analysis, using a backwards selection procedure to derive the final model. A type 1 error rate ≤5% (p≤0.05) was considered significant in the final model. 27.4 ± 5.8 13.9 ± 3.0 13.3 ± 6.3 * For the purpose of statistical analysis, the ethnicity of patients classified as "Afro-Caribbean", "Asian" and "Others" was grouped as "Non-Caucasian", 77% "Caucasian" versus 23% "NonCaucasian". † Normally distributed data, results expressed as mean ± standard deviation (SD). ‡ Non-normally distributed data, results expressed as median (interquartile range, IQR). § For the purpose of statistical analysis, smoking status was arranged into 2 categories, "non-smoker" versus "current smoker and ex-smoker", 63% Post-print cite as: Chan, W., Jones, D., Bosch, J.A., McTernan, P.G., Inston, N., Moore, S., Kaur, O., Phillips, A.C. & Borrows, R. (2014). Hypervolemia and blood pressure in prevalent kidney transplant recipients. For the purpose of statistical analysis, smoking status was arranged into 2 categories, "non-smoker" versus "the combination of current smoker and ex-smoker", 63% and 37% of patients respectively. ‡ For the purpose of statistical analysis, the ethnicity of patients classified as "Afro-Caribbean", "Asian" and "Others" was grouped as "Non-Caucasian", 77% "Caucasian" versus 23% "NonCaucasian". For the purpose of statistical analysis, smoking status was arranged into 2 categories, "non-smoker" versus "the combination of current smoker and ex-smoker", 63% and 37% of patients respectively.
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